It is widely believed that the neoantigens derived from tumor-specific somatic mutations have the potential to be recognized by the immune system and allow specific CD8+ cytotoxic T cells to kill cancer cells as a consequence of activated immune response [33, 36]. The gene discussed is CD8A; the disease is neoplasm.